Editorial: Emerging treatment approaches for substance use disorders - Takeaways - MDSpire

Editorial: New Strategies in the Management of Substance Use Disorders

  • By

  • David Martinez Garza

  • Ilya O. Blokhin

  • Jonathan Brett

  • Ihsan Salloum

  • July 21, 2026

Share

  • 1

    Since 1951, only eight medications have been FDA-approved for substance use disorders (SUDs), despite their significant prevalence and impact.

  • 2

    Emerging treatments, including psychedelics like psilocybin and ketamine, show promise in improving outcomes for patients with SUDs.

  • 3

    Non-pharmacological interventions, such as cognitive behavioral therapy and digital courses, have been employed with varying efficacy in treating SUDs.

  • 4

    Recent studies suggest that combining pharmacotherapy with psychosocial interventions can reduce readmission risks for patients with SUDs.

  • 5

    Research initiatives are exploring personalized treatment approaches and the integration of neuroimaging to enhance therapeutic interventions for SUDs.

Original Source(s)

Editorial: Emerging treatment approaches for substance use disorders

  • by David Martinez Garza, Ilya O. Blokhin, Jonathan Brett, Ihsan Salloum

  • July 21, 2026

Related Content

ADHD Stimulant Misuse Under Review

High-frequency misuse remains associated with polysubstance use, while no studies evaluated long-term physical health outcomes.

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.